Drug intelligence / Profile preview

NMT.002

Development stage: Preclinical
Lead developer: Neumirna Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

NMT.002 is an antisense oligonucleotide (ASO) drug candidate developed by Neumirna Therapeutics ApS. It is in preclinical development for the treatment of nervous system diseases, with a primary focus on Parkinson's disease. The drug is designed to modulate gene expression at the RNA level, which may offer therapeutic benefits in neurodegenerative and potentially metabolic disorders[1].

Targets

miR-27b (MicroRNA-27b)

Beyond the preview

Go deeper on NMT.002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMT.002.

Explore the full profile